SCHEMBL19856053

SCHEMBL19856053

C=CCCC1CCC(C2CCC(c3ccc(NC(=O)C(=C)C)cc3)CC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ CYP2C9 P11712 1/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ HDAC3 O15379 2/20 0.37
▸ HDAC11 Q96DB2 2/20 0.37
▸ HDAC8 Q9BY41 2/20 0.37
▸ HDAC6 Q9UBN7 2/20 0.37
▸ MITF O75030 1/20 0.36
▸ KLF5 Q13887 1/20 0.36
▸ SLC18A3 Q16572 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ DGAT1 O75907 5/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19856054 0.85 TGM2 (0.42) ALDH1A1LMNAMAPTCYP2C9IDO1
SCHEMBL19856067 0.84 MAPT (0.44) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL19856062 0.83 MAPT (0.44) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL19856064 0.83 MAPT (0.44) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL19854501 0.83 ALDH1A1 (0.56) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL20370415 0.80 MAPT (0.47) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL19854507 0.79 MAPT (0.46) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL19855993 0.79 CYP2C9 (0.38) ALDH1A1LMNAMAPTCYP2C9ESR2
SCHEMBL19856055 0.77 MAPT (0.44) ALDH1A1LMNAMAPTRXFP1CYP2C9
SCHEMBL19855139 0.76 MAPT (0.44) ALDH1A1LMNAMAPTRXFP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2020-05-26 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, MBD2, PAXBP1 ALDH1A1 3826/4885LMNA 1840/4885MAPT 1073/4885
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device SP1, MBD2, PAXBP1 ALDH1A1 3826/4885LMNA 1840/4885MAPT 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback